Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS CIT Group ( CIT - Get Report) estimates lowered at Sterne AgeeCIT estimates lowered through 2011. Incorporating debt repayments. Maintain $50 price target and Buy rating. Clean Harbors ( CLH - Get Report) upgraded at JP Morgan from Neutral to Overweight. $70 price target. Stock is attractive, following a 13% pullback. Cree ( CREE - Get Report) downgraded at Wunderlich from Hold to Sell. $25 price target. The weakness is global chip bookings could soon accelerate. Dendreon ( DNDN) target cut at ThinkEquity to $21. Pricing in full restructuring costs. Buy rating. Diamond Foods ( DMND) target raised at KeyBanc to $85. Ongoing investments in advertising and new products. Buy rating. Ecolab ( ECL) target raised at Citigroup to $57. Solid product pipeline and good progress on EMEA restructuring. Buy rating. The Hartford ( HIG) estimates, target lowered at UBS. Shares of HIG now seen reaching $38. Estimates also cut on likely large 3Q11 deferred acquisition costs. Buy rating. Hill-Rom ( NYT - Get Report) rated new Overweight at Morgan Stanley. $37 price target. Company can deliver consistent growth over the coming years. Kroger ( KR) estimates, target lowered at Jefferies.Shares of KR now seen reaching $26. Estimates also lowered on flat volumes. Buy rating. Lululemon ( LULU - Get Report) estimates, target increased at Credit Suisse.LULU estimates were raised through 2014. Higher sales is driving wider margins. Neutral rating and new $59 price target. Lululemon estimates, target increased at Jefferies.Shares of LULU now seen reaching $59. Estimates also raised on continued global strength in market demand. Hold rating. McDonalds ( MCD) estimates, target cut at UBS.Shares of MCD now seen reaching $96. Estimates also lowered following weaker than expected August SSS. Buy rating. Mosaic ( MOS) upgraded at Goldman to Buy. Company is leveraged to an improving supply/demand outlook. Myriad Genetics ( MYGN) upgraded at Auriga from Hold to Buy. $24 price target. Company can deliver solid growth in 2012. New York Times ( NYT - Get Report) estimates, target lowered at UBS. Shares of NYT now seen reaching $8. Estimates also lowered on apparent slowing in September. Neutral rating. Oracle ( ORCL) added to Conviction Buy List at Goldman. Pullback has created an attractive buying opportunity. $33 price target.
Pfizer ( PFE - Get Report) estimates raised at Jefferies through 2012. Multiple should expand as pipeline visibility continues to build. Buy rating. Public Service ( PEG) numbers raised at Goldman. Shares of PEG now seen reaching $35. Estimates also increased, as the company is seeing lower costs. Buy rating. Research In Motion ( RIMM) estimates raised at Sterne Agee. RIMM estimates increased through 2013. Anticipate decent quarter. Maintain $35 price target and Buy rating. Smithfield Foods ( SFD) estimates reduced at JP Morgan.SFD estimates were cut through 2013. Visibility is decreasing for pork prices. Neutral rating and $21 price target. Teleflex ( TFX) rated new Equal-weight at Morgan Stanley. $61 price target. Company can expand its margins. Varian Medical ( VAR) rated new Equal-weight at Morgan Stanley. Company is seeing weaker orders in developed markets. End of report.